• Explore /
  • Poster
  • / BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.

Abstract Poster

Authors

Scott Tagawa

Scott T. Tagawa

Weill Cornell Medicine, New York, NY

Scott T. Tagawa , Jingsong Zhang , Paul Monk III, Xinhua Zhu , Robert Jones , Mark David Linch , Dan Costin , Johann S. De Bono , Lawrence Ivan Karsh , Daniel P. Petrylak , Pascal Borderies , Rashmi Majali Deshpande , Vincent O'Neill , Rahul Raj Aggarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03910660

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 126)

DOI

10.1200/JCO.2022.40.6_suppl.126

Abstract #

126

Poster Bd #

F12

Abstract Disclosures

Similar Posters

First Author: Jingsong Zhang

First Author: Rahul Raj Aggarwal

First Author: Rahul Raj Aggarwal

First Author: Evan Y. Yu